All the News
Be part of our journey and stay up to date with our latest announcements.
Featured News (06)
01Don’t Miss Our Latest Updates
Upcoming Events (02)
02Let’s Connect
Beyond Protein Targets: Why The Regulatory Genome Could Redefine RNA Medicine (Pt. 1)
Advancing RNA
HAYA Therapeutics Receives FDA Fast Track Designation for HTX-001
Fast Track Designation for HTX-001 for the treatment of symptomatic nHCM.
Interview with Samir Ounzain, CEO and Co-Founder of HAYA Therapeutics
The BioHub – by Avetix
ECCB 2026
Meet Samir Ounzain, CEO & Co-Founder
ESC 2026
Meet Jordan Shin, CMO
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001
An Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis
HAYA's CEO Samir Ounzain Recognized as One of the In Vivo’s 2026 Rising Leaders
Citeline – In Vivo
HAYA’s Dark Genome Play: Turning ‘Junk DNA’ Into Drug Targets
Citeline
The cryptic messages of our genome
Technology Outlook